Resources
8 Results (showing 1 - 8)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 10/23/2020 (updated 4/3/2024)
These pilot study results suggest comparable safety and effectiveness of unobserved and office induction and point toward utilization of non-inferiority design during future definitive protocol development.
Posted 10/23/2020 (updated 4/3/2024)
This article offers data regarding offering buprenorphine treatment at a public hospital primary care setting using a home, unobserved induction protocol.
Posted 3/29/2024
The Centers for Disease Control and Prevention (CDC) has naloxone trainings and fact sheets available for clinicians. The trainings and fact sheets can help clinicians raise awareness about the benefits of naloxone by talking with patients and their family, friends, and caregivers.
Posted 5/22/2020 (updated 3/28/2024)
As a response to the ongoing opioid crisis, every US state has increased access to naloxone through a variety of expanded prescribing methods, such as standing orders or protocols. This reports examines the impact of a standing order for rural Georgia pharmacies.
Posted 5/12/2020 (updated 3/28/2024)
Corrections-Based Responses to the Opioid Epidemic: Lessons from New York State’s Overdose Education and Naloxone Distribution Program focuses on the efforts of NYS to implement an overdose education and naloxone distribution program that teaches all soon-to-be released people in state correctional facilities—as well as their families and corrections staff—about the risks of opioid use, trains them in the use of naloxone, and offers it to them free of charge at release.
Posted 11/21/2019 (updated 3/28/2024)
Opioid overdose is reversible through the timely administration of naloxone, which has been used by emergency medical services for decades.
Posted 4/27/2020 (updated 3/28/2024)
To mitigate the opioid overdose crisis, states have implemented a variety of legal interventions aimed at increasing access to the opioid antagonist naloxone. Recently, Virginia and Vermont mandated the coprescription of naloxone for potentially at-risk patients.
Posted 11/19/2019 (updated 3/25/2024)
Although typically delivered via intramuscular or intravenous injection, naloxone may be delivered via intranasal spray device.